JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

A novel prognostic signature based on m5C‑related LncRNAs and its immunological characteristics in colon adenocarcinoma

  • 0Department of Gastroenterology, Jiangsu Funing People's Hospital, Funing, China.
Discover Oncology +

|

March 17, 2025

|

March 17, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

A new six-long non-coding RNA (lncRNA) signature linked to 5-methylcytosine (m5C) modification accurately predicts colon adenocarcinoma (COAD) prognosis and reveals immune microenvironment insights.

Area Of Science

  • Epigenetics and RNA Modifications
  • Cancer Genomics
  • Molecular Oncology

Background

  • Colon adenocarcinoma (COAD) presents significant mortality due to treatment resistance.
  • 5-methylcytosine (m5C) RNA modification is implicated in cancer development.
  • Identifying novel prognostic markers is crucial for COAD management.

Purpose Of The Study

  • To develop and validate an m5C-related long non-coding RNA (lncRNA) signature for COAD prognosis.
  • To explore the signature's relationship with the tumor immune microenvironment.
  • To identify potential therapeutic targets in COAD.

Main Methods

  • Utilized TCGA and GEO datasets to analyze m5C regulatory genes and associated lncRNAs in COAD.
  • Constructed a prognostic signature using univariate Cox and LASSO regression.
  • Performed survival, ROC, functional enrichment, immune infiltration, and drug sensitivity analyses.

Main Results

  • A six-lncRNA signature associated with m5C regulators was established for COAD prognosis.
  • The signature accurately predicted patient outcomes, independent of clinical features.
  • Significant correlations were found between the risk signature and immune cell infiltration; NR2F2-AS1 was validated as a risk factor.

Conclusions

  • The developed m5C-related lncRNA signature is a robust prognostic tool for COAD.
  • This signature offers valuable insights into the COAD tumor immune microenvironment.
  • The findings suggest potential avenues for targeted therapy in colon adenocarcinoma.

Keywords: